Skip to content
OpenCapital
Get started

Kura Oncology KURA AOCI - Available-for-Sale Securities, Net of Tax

AOCI - Available-for-Sale Securities, Net of Tax at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
——

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M—
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$919.7M+81.6%
Enterprise value$904.89M+90.7%
P/S12.8×+3.5×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's aoci - available-for-sale securities, net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's AOCI - available-for-sale securities, net of tax?
Kura Oncology (KURA) reported AOCI - available-for-sale securities, net of tax of -$380K in Q1 2026.